Linagliptin meets Phase III endpoints

Linagliptin met the primary endpoint in each of four Phase III trials to treat Type II diabetes, Boehringer Ingelheim GmbH (Ingelheim, Germany) said in presentations at the American Diabetes Association meeting in Orlando. The trials evaluated linagliptin in combination with Actos pioglitazone, as an add-on to metformin and sulfonylurea, as an add-on to metformin, and as monotherapy. Each linagliptin treatment regimen significantly reduced HbA1c from baseline to week 24 vs. their respective control treatments (p<0.0001 for all). Linagliptin is a xanthine-based dipeptidyl peptidase-4 (DPP-4) inhibitor (See BioCentury, June 15, 2009). ...